These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30717761)

  • 21. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia.
    Feller CN; Adams JA; Friedland DR; Poetker DM
    Am J Otolaryngol; 2022; 43(3):103409. PubMed ID: 35216850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
    Xu C; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hereditary Haemorrhagic Telangiectasia, an Inherited Vascular Disorder in Need of Improved Evidence-Based Pharmaceutical Interventions.
    Snodgrass RO; Chico TJA; Arthur HM
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33513792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations.
    Balachandar S; Graves TJ; Shimonty A; Kerr K; Kilner J; Xiao S; Slade R; Sroya M; Alikian M; Curetean E; Thomas E; McConnell VPM; McKee S; Boardman-Pretty F; Devereau A; Fowler TA; Caulfield MJ; Alton EW; Ferguson T; Redhead J; McKnight AJ; Thomas GA; ; Aldred MA; Shovlin CL
    Am J Med Genet A; 2022 Mar; 188(3):959-964. PubMed ID: 34904380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High output cardiac failure in 3 patients with hereditary hemorrhagic telangiectasia and hepatic vascular malformations, evaluation of treatment.
    Olsen LB; Kjeldsen AD; Poulsen MK; Kjeldsen J; Fialla AD
    Orphanet J Rare Dis; 2020 Nov; 15(1):334. PubMed ID: 33243256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
    Azzopardi N; Dupuis-Girod S; Ternant D; Fargeton AE; Ginon I; Faure F; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Leguy-Seguin V; Rivière S; Corre R; Bailly S; Paintaud G
    MAbs; 2015; 7(3):630-7. PubMed ID: 25751241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.
    Latif MA; Sobreira NLD; Guthrie KS; Motaghi M; Robinson GM; Shafaat O; Gong AJ; Weiss CR
    Am J Med Genet A; 2021 Jul; 185(7):1981-1990. PubMed ID: 33768677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.
    Dupuis-Girod S; Ambrun A; Decullier E; Fargeton AE; Roux A; Bréant V; Colombet B; Rivière S; Cartier C; Lacombe P; Chinet T; Blivet S; Blondel JH; Gilbert-Dussardier B; Dufour X; Michel J; Harle JR; Dessi P; Faure F
    JAMA; 2016 Sep; 316(9):934-42. PubMed ID: 27599328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
    Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H
    Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians.
    Al-Samkari H
    Semin Thromb Hemost; 2022 Jul; 48(5):514-528. PubMed ID: 35226946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.
    Karlsson T; Cherif H
    Ups J Med Sci; 2018 Sep; 123(3):153-157. PubMed ID: 30251589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia: Be Cautious: A Case Report.
    Maestraggi Q; Bouattour M; Toquet S; Jaussaud R; Kianmanesh R; Durand F; Servettaz A
    Medicine (Baltimore); 2015 Nov; 94(46):e1966. PubMed ID: 26579805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide.
    Lacout A; Marcy PY; El Hajjam M; Lacombe P
    Med Hypotheses; 2013 May; 80(5):587-8. PubMed ID: 23452644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab in the treatment of hereditary hemorrhagic telangiectasia.
    Kanellopoulou T; Alexopoulou A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1315-23. PubMed ID: 23815519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
    Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
    Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding.
    Beckman JD; Li Q; Hester ST; Leitner O; Smith KL; Kasthuri RS
    Orphanet J Rare Dis; 2020 Jul; 15(1):185. PubMed ID: 32660636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
    Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
    Epperla N; Hocking W
    Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future treatments for hereditary hemorrhagic telangiectasia.
    Robert F; Desroches-Castan A; Bailly S; Dupuis-Girod S; Feige JJ
    Orphanet J Rare Dis; 2020 Jan; 15(1):4. PubMed ID: 31910860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.